GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beam Therapeutics Inc (NAS:BEAM) » Definitions » Effective Interest Rate on Debt %
中文

Beam Therapeutics (Beam Therapeutics) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Beam Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Beam Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.0 Mil. Beam Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $172.6 Mil. Therefore, Beam Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.


Beam Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Beam Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beam Therapeutics Effective Interest Rate on Debt % Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 0.73 - 0.01 - -

Beam Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Beam Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Beam Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beam Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Effective Interest Rate on Debt % falls into.



Beam Therapeutics Effective Interest Rate on Debt % Calculation

Beam Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (179.005+172.689)/ 2 )
=-1  *  0/175.847
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=168.625 + 10.38
=179.005

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=159.911 + 12.778
=172.689

Beam Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  0/( (172.588+172.689)/ 2 )
=-1  *  0/172.6385
=0.00 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=160.637 + 11.951
=172.588

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=159.911 + 12.778
=172.689

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Beam Therapeutics  (NAS:BEAM) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Beam Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Beam Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Beam Therapeutics (Beam Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Executives
Christine Bellon officer: Chief Legal Officer BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Amy Simon officer: Chief Medical Officer BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Giuseppe Ciaramella officer: President & CSO C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
John M. Evans director, officer: CEO C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Terry-ann Burrell officer: CFO C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Kathleen E Walsh director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Stephen C Knight director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Mark Fishman director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631